Works Cited

1. Marks M, Cohen IG. Psychedelic therapy: a roadmap for wider acceptance and utilization. Nat Med. 2021;27(10):1669-1671.

2. Alcohol and Drug Foundation (ADF). Dissociatives. Available at Last accessed June 13, 2023.

3. Adams JD Jr, Garcia C. Spirit, mind and body in Chumash healing. Evid Based Complement Alternat Med. 2005;2(4):459-463.

4. Evans WC, Woolley JG. The alkaloids of Datura meteloides D.C. J Chem Soc Perkin1. 1965;4936-4939.

5. De Gregorio D, Aguilar-Valles A, Preller KH, et al. Hallucinogens in mental health: preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine. J Neurosci. 2021;41(5):891-900.

6. US Food and Drug Administration (FDA). Breakthrough Therapy. Available at Last accessed June 13, 2023.

7. Oregon Health Authority (OHA). Oregon Psilocybin Services. Available at Last accessed June 13, 2023.

8. Muthukumaraswamy SD, Forsyth A, Lumley T. Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol. 2021;14(9):1133-1152.

9. Rosenbaum D, Weissman C, Anderson T, et al. Microdosing psychedelics: demographics, practices, and psychiatric comorbidities.J Psychopharmacol. 2020;34(6):612-622.

10. Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. 2018;142:143-166.

11. Borowiak KS, Ciechanowski K, Waloszczyk P. Psilocybin mushroom (Psilocybe semilanceata) intoxication with myocardial infarction.J Toxicol Clin Toxicol. 1998;36(1-2):47-49.

12. Anderson T, Petranker R, Christopher A, et al. Psychedelic microdosing benefits and challenges: an empirical codebook. Harm Reduct J. 2019;16(1):43.

13. Cavanna F, Muller S, de la Fuente LA, et al. Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study.Transl Psychiatry. 2022;12(1):307.

14. Dos Santos RG, Osório FL, Crippa JAS, Riba J, Zuardi AW, Hallak JEC. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.Ther Adv Psychopharmacol. 2016;6(3):193-213.

15. Schenberg EE. Ayahuasca and cancer treatment. SAGE Open Med. 2013;1:2050312113508389.

16. Pomilio AB, Vitale AA, Ciprian-Ollivier J, Cetkovich-Bakmas M, Gómez R, Vázquez G. Ayahoasca: an experimental psychosis that mirrors the transmethylation hypothesis of schizophrenia. J Ethnopharmacol. 1999;65(1):29-51.

17. Barbosa PCR, Mizumoto S, Bogenschutz MP, Strassman RJ. Health status of ayahuasca users. Drug Test Anal. 2012;4(7-8):601-609.

18. Lesiak AD, Musah RA. Application of ambient ionization high resolution mass spectrometry to determination of the botanical provenance of the constituents of psychoactive drug mixtures. Forensic Sci Int. 2016;266:271-280.

19. González D, Cantillo J, Pérez I, et al. Therapeutic potential of ayahuasca in grief: a prospective, observational study. Psychopharmacology (Berl). 2020;237(4):1171-1182.

20. Ona G, Kohek M, Massaguer T, et al. Ayahuasca and public health: health status, psychosocial well-being, lifestyle, and coping strategies in a large sample of ritual ayahuasca users. J Psychoactive Drugs. 2019;51(2):135-145.

21. Riba J, Rodríguez-Fornells A, Urbano G, et al. Subjective effects and tolerability of the South American psychoactive beverage ayahuasca in healthy volunteers. Psychopharmacology (Berl). 2001;154(1):85-95.

22. Uthaug MV, van Oorsouw K, Kuypers KPC, et al. Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution. Psychopharmacology (Berl). 2018;235(10):2979-2989.

23. Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49(4):655-663.

24. Kaasik H, Souza RCZ, Zandonadi FS, Tófoli LF, Sussulini A. Chemical composition of traditional and analog ayahuasca. J Psychoactive Drugs. 2021;53(1):65-75.

25. dos Santos RG. A critical evaluation of reports associating ayahuasca with life-threatening adverse reactions. J Psychoactive Drugs. 2013;45(2):179-188.

26. Sanches RF, de Lima Osório F, Dos Santos RG, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol. 2016;36(1):77-81.

27. Osório F de L, Sanches RF, Macedo LR, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Braz J Psychiatry. 2015;37(1):13-20.

28. Thomas G, Lucas P, Capler NR, Tupper KW, Martin G. Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada. Curr Drug Abuse Rev. 2013;6(1):30-42.

29. Siebert DJ. Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol. 1994;43(1):53-56.

30. Mello SM, Soubhia PC, Silveira G, et al. Effect of ritualistic consumption of ayahuasca on hepatic function in chronic users.J Psychoactive Drugs. 2019;51(1):3-11.

31. Dos Santos RG, Osório F de L, Rocha JM, et al. Ayahuasca improves self-perception of speech performance in subjects with social anxiety disorder: a pilot, proof-of-concept, randomized, placebo-controlled trial. J Clin Psychopharmacol. 2021;41(5):540-550.

32. Dos Santos RG, Grasa E, Valle M, et al. Pharmacology of ayahuasca administered in two repeated doses. Psychopharmacology (Berl). 2012;219(4):1039-1053.

33. dos Santos RG. Safety and side effects of ayahuasca in humans--an overview focusing on developmental toxicology. J Psychoactive Drugs. 2013;45(1):68-78.

34. Sklerov J, Levine B, Moore KA, King T, Fowler D. A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. J Anal Toxicol. 2005;29(8):838-841.

35. Palma-Álvarez RF, Grau-López L, Ros-Cucurull E, et al. Psychosis induced by abuse of ayahuasca: a case report. Rev Colomb Psiquiatr (Engl Ed). 2021;50(1):43-46.

36. Zhao T, He YQ, Wang J, Ding KM, Wang CH, Wang ZT. Inhibition of human cytochrome P450 enzymes 3A4 and 2D6 by β-carboline alkaloids, harmine derivatives. Phytother Res. 2011;25(11):1671-1677.

37. Callaway JC, Grob CS. Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. J Psychoactive Drugs. 1998;30(4):367-369.

38. Kremer C, Paulke A, Wunder C, Toennes SW. Variable adverse effects in subjects after ingestion of equal doses of Argyreia nervosa seeds. Forensic Sci Int. 2012;214(1-3):e6-e8.

39. López-Giménez JF, González-Maeso J. Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways. Curr Top Behav Neurosci. 2018;36:45-73.

40. Paulke A, Kremer C, Wunder C, Wurglics M, Schubert-Zsilavecz M, Toennes SW. Identification of legal highs--ergot alkaloid patterns in two Argyreia nervosa products. Forensic Sci Int. 2014;242:62-71.

41. Al-Assmar SE. The seeds of the Hawaiian baby woodrose are a powerful hallucinogen. Arch Intern Med. 1999;159(17):2090.

42. Shawcross WE. Recreational use of ergoline alkaloid from Argyreia nervosa. J Psychoactive Drugs. 1983;15(4):251-259.

43. Vigor C, Fabre N, Fourasté I, Moulis C. Neoclerodane diterpenoids from Croton eluteria. J Nat Prod. 2002;65(8):1180-1182.

44. Mazoyer C, Carlier J, Boucher A, Péoc'h M, Lemeur C, Gaillard Y. Fatal case of a 27-year-old male after taking iboga in withdrawal treatment: GC-MS/MS determination of ibogaine and ibogamine in iboga roots and postmortem biological material. J Forensic Sci. 2013;58(6):1666-1672.

45. Rodriguez P, Urbanavicius J, Prieto JP, et al. A single administration of the atypical psychedelic ibogaine or its metabolite noribogaine induces an antidepressant-like effect in rats. ACS Chem Neurosci. 2020;11(11):1661-1672.

46. Grogan J, Gerona R, Snow JW, Kao L. Ibogaine consumption with seizure-like episodes, QTc-prolongation, and captured cardiac dysrhythmias. J Emerg Med. 2019;57(4):e99-e104.

47. Steinberg C, Deyell MW. Cardiac arrest after ibogaine intoxication. J Arrhythm. 2018;34(4):455-457.

48. Litjens RPW, Brunt TM. How toxic is ibogaine? Clin Toxicol (Phila). 2016;54(4):297-302.

49. Malcolm BJ, Polanco M, Barsuglia JP. Changes in withdrawal and craving scores in participants undergoing opioid detoxification utilizing ibogaine. J Psychoactive Drugs. 2018;50(3):256-265.

50. Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J. Treatment of acute opioid withdrawal with ibogaine. Am J Addict. 1999;8(3):234-242.

51. Sheppard SG. A preliminary investigation of ibogaine: case reports and recommendations for further study. J Subst Abuse Treat. 1994;11(4):379-385.

52. Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.

53. Davis AK, Barsuglia JP, Windham-Herman AM, Lynch M, Polanco M. Subjective effectiveness of ibogaine treatment for problematic opioid consumption: short- and long-term outcomes and current psychological functioning. J Psychedelic Stud. 2017;1(2):65-73.

54. O'Connell CW, Gerona RR, Friesen MW, Ly BT. Internet-purchased ibogaine toxicity confirmed with serum, urine, and product content levels. Am J Emerg Med. 2015;33(7):985.e5-e6.

55. Vlaanderen L, Martial LC, Franssen EJF, van der Voort PHJ, Oosterwerff E, Somsen GA. Cardiac arrest after ibogaine ingestion.Clin Toxicol (Phila). 2014;52(6):642-643.

56. Hoelen DWM, Spiering W, Valk GD. Long-QT syndrome induced by the antiaddiction drug ibogaine. N Engl J Med. 2009;360(3):308-309.

57. Paling FP, Andrews LM, Valk GD, Blom HJ. Life-threatening complications of ibogaine: three case reports. Neth J Med. 2012;70(9):422-424.

58. Pleskovic A, Gorjup V, Brvar M, Kozelj G. Ibogaine-associated ventricular tachyarrhythmias. Clin Toxicol (Phila). 2012;50(2):157.

59. Henstra M, Wong L, Chahbouni A, Swart N, Allaart C, Sombogaard F. Toxicokinetics of ibogaine and noribogaine in a patient with prolonged multiple cardiac arrhythmias after ingestion of internet purchased ibogaine. Clin Toxicol (Phila). 2017;55(6):600-602.

60. Knuijver T, Schellekens A, Belgers M, et al. Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study. Addiction. 2022;117(1):118-128.

61. Papadodima SA, Dona A, Evaggelakos CI, Goutas N, Athanaselis SA. Ibogaine related sudden death: a case report. J Forensic Leg Med. 2013;20(7):809-811.

62. Meisner JA, Wilcox SR, Richards JB. Ibogaine-associated cardiac arrest and death: case report and review of the literature. Ther Adv Psychopharmacol. 2016;6(2):95-98.

63. Aćimović T, Atanasijević T, Denić K, Lukić V, Popović V, Bogdanović M. Death due to consumption of ibogaine: case report. Forensic Sci Med Pathol. 2021;17(1):126-129.

64. U.S. Drug Enforcement Administration Diversion Control Division. Code of Federal Regulations: §1307.31 Native American Church. Available at Last accessed June 12, 2023.

65. Glue P, Winter H, Garbe K, et al. Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers. J Clin Pharmacol. 2015;55(6):680-687.

66. Brown RT, Nicholas CR, Cozzi NV, et al. Pharmacokinetics of escalating doses of oral psilocybin in healthy adults. Clin Pharmacokinet. 2017;56(12):1543-1554.

67. Higgins GA, Carroll NK, Brown M, et al. Low doses of psilocybin and ketamine enhance motivation and attention in poor performing rats: evidence for an antidepressant property. Front Pharmacol. 2021;12:640241.

68. Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci U S A. 2021;118(17):e2022489118.

69. Winter JC, Rice KC, Amorosi DJ, Rabin RA. Psilocybin-induced stimulus control in the rat. Pharmacol Biochem Behav. 2007;87(4):472-480.

70. Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry. 2012;72(11):898-906.

71. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181-1197.

72. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29(3):289-299.

73. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.Arch Gen Psychiatry. 2011;68(1):71-78.

74. Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol. 2018;32(1):49-69.

75. Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berl). 2004;172(2):145-156.

76. Bienemann B, Ruschel NS, Campos ML, Negreiros MA, Mograbi DC. Self-reported negative outcomes of psilocybin users: a quantitative textual analysis. PLoS One. 2020;15(2):e0229067.

77. Carbonaro TM, Johnson MW, Griffiths RR. Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan. Psychopharmacology (Berl). 2020;237(8):2293-2304.

78. Anderson BT, Danforth A, Daroff R, et al. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. EClinicalMedicine. 2020;27:100538.

79. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165-1180.

80. Vargas AS, Luís Â, Barroso M, Gallardo E, Pereira L. Psilocybin as a new approach to treat depression and anxiety in the context of life-threatening diseases-a systematic review and meta-analysis of clinical trials. Biomedicines. 2020;8(9):331.

81. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384(15):1402-1411.

82. Carhart-Harris RL, Roseman L, Bolstridge M, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2017;7(1):13187.

83. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619-627.

84. Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78(5):481-489.

85. Gukasyan N, Davis AK, Barrett FS, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. J Psychopharmacol. 2022;36(2):151-158.

86. Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2022;79(10):953-962.

87. Bickel M, Ditting T, Watz H, et al. Severe rhabdomyolysis, acute renal failure and posterior encephalopathy after "magic mushroom" abuse. Eur J Emerg Med. 2005;12(6):306-308.

88. van Poorten JF, Stienstra R, Dworacek B, Moleman P, Rupreht J. Physostigmine reversal of psilocybin intoxication. Anesthesiology. 1982;56(4):313.

89. Dahmane E, Hutson PR, Gobburu JVS. Exposure-response analysis to assess the concentration-QTc relationship of psilocybin/psilocin. Clin Pharmacol Drug Dev. 2021;10(1):78-85.

90. Becker AM, Holze F, Grandinetti T, et al. Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Clin Pharmacol Ther. 2022;111(4):886-895.

91. Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol. 2011;25(11):1434-1452.

92. Carbonaro TM, Bradstreet MP, Barrett FS, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol. 2016;30(12):1268-1278.

93. US Drug Enforcement Administration (DEA). Peyote and Mescaline Drug Fact Sheet. Available at Last accessed June 14, 2023.

94. Franco-Molina M, Gomez-Flores R, Tamez-Guerra P, Tamez-Guerra R, Castillo-Leon L, Rodríguez-Padilla C. In vitro immunopotentiating properties and tumour cell toxicity induced by Lophophora williamsii (peyote) cactus methanolic extract. Phytother Res. 2003;17(9):1076-1081.

95. Carstairs SD, Cantrell FL. Peyote and mescaline exposures: a 12-year review of a statewide poison center database. Clin Toxicol (Phila). 2010;48(4):350-353.

96. Nolte KB, Zumwalt RE. Fatal peyote ingestion associated with Mallory-Weiss lacerations. West J Med. 1999;170(6):328.

97. Lu BY, Woofter C, Escalona R. A case of prolonged peyote-induced psychosis resolved by sleep. J Clin Psychiatry. 2004;65(10):1433-1434.

98. Pelner L. Peyote cult, mescaline hallucinations, and model psychosis. N Y State J Med. 1967;67(21):2838-2843.

99. Valdés LJ III, Díaz JL, Paul AG. Ethnopharmacology of ska María Pastora (Salvia divinorum, Epling and Játiva-M.). J Ethnopharmacol. 1983;7(3):287-312.

100. Valdés LJ III. Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A. J Psychoactive Drugs. 1994;26(3):277-283.

101. El-Khoury J, Sahakian N. The association of Salvia divinorum and psychotic disorders: a review of the literature and case series.J Psychoactive Drugs. 2015;47(4):286-292.

102. Halpern JH. Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol Ther. 2004;102(2):131-138.

103. González D, Riba J, Bouso JC, Gómez-Jarabo G, Barbanoj MJ. Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend. 2006;85(2):157-162.

104. Roth BL, Baner K, Westkaemper R, et al. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A. 2002;99(18):11934-11939.

105. Butelman ER, Harris TJ, Kreek MJ. The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology (Berl). 2004;172(2):220-224.

106. Doss MK, May DG, Johnson MW, et al. The acute effects of the atypical dissociative hallucinogen Salvinorin A on functional connectivity in the human brain. Sci Rep. 2020;10(1):16392.

107. Vázquez-León P, Arenas-Martínez U, Córdova-Maqueda D, Fregoso-Aguilar T, Ramírez-San Juan E, Miranda-Páez A. Salvia divinorum increases alcohol intake and tonic immobility whilst decreasing food intake in Wistar rats. Acta Neurobiol Exp (Wars). 2021;81(1):34-42.

108. Addy PH, Garcia-Romeu A, Metzger M, Wade J. The subjective experience of acute, experimentally-induced Salvia divinorum inebriation. J Psychopharmacol. 2015;29(4):426-435.

109. Bücheler R, Gleiter CH, Schwoerer P, Gaertner I. Use of nonprohibited hallucinogenic plants: increasing relevance for public health? A case report and literature review on the consumption of Salvia divinorum (Diviner's Sage). Pharmacopsychiatry. 2005;38(1):1-5.

110. Gómez-Sousa M, Jiménez-Garrido DF, Ona G, et al. Acute psychological adverse reactions in first-time ritual ayahuasca users: a prospective case series. J Clin Psychopharmacol. 2021;41(2):163-171.

111. Gertsch JH, Wood C. Case report: an ingestion of Hawaiian baby woodrose seeds associated with acute psychosis. Hawaii Med J. 2003;62(6):127, 129.

112. Paulke A, Kremer C, Wunder C, Toennes SW. Analysis of lysergic acid amide in human serum and urine after ingestion of Argyreia nervosa seeds. Anal Bioanal Chem. 2012;404(2):531-538.

113. Schenberg EE, de Castro Comis MA, Chaves BR, da Silveira DX. Treating drug dependence with the aid of ibogaine: a retrospective study. J Psychopharmacol. 2014;28(11):993-1000.

114. Asua I. Growing menace of ibogaine toxicity. Br J Anaesth. 2013;111(6):1029-1030.

115. Alper KR, Stajić M, Gill JR. Fatalities temporally associated with the ingestion of ibogaine. J Forensic Sci. 2012;57(2):398-412.

116. Preller KH, Duerler P, Burt JB, et al. Psilocybin induces time-dependent changes in global functional connectivity. Biol Psychiatry. 2020;88(2):197-207.

117. Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR. The experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis. Psychiatry Res. 2020;284:112749.

118. Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). 2018;235(2):399-408.

119. Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: from anecdotes and misinformation to systematic science. J Psychopharmacol. 2022;36(3):258-272.

120. Uthaug MV, Mason NL, Toennes SW, et al. A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats. Psychopharmacology (Berl). 2021;238(7):1899-1910.

121. U.S. Drug Enforcement Administration. Drug Scheduling. Available at Last accessed June 15, 2023.

Evidence-Based Practice Recommendations Citations

1. U.S. Department of Veterans Affairs. Evidence Brief: Psychedelic Medications for Mental Health and Substance Use Disorders. Washington, DC: U.S. Government Printing Office; 2022. Available at Last accessed June 16, 2023.

Copyright © 2023 NetCE, PO Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.